Vasculitis & polymyalgia rheumatica
Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort
Authors' conclusion
Glucocorticoid-sparing management of G-CSF-associated LVV may be a safe and effective approach.
Study context
- Population
- Patients with cancer diagnosed with large-vessel vasculitis (LVV) following G-CSF administration, April 2020–December 2024, Japanese cancer centreof 4708 patients (0.4%)
- Participants
- 19 patients
- Exposure
- Non-GC treatment (mainly NSAIDs) vs GC for inadequate response to or intolerance of NSAIDs
- Non-glucocorticoid treatmentn = 18
- Glucocorticoidsn = 1reference
- Outcome
- Remission rate in patients treated without GC
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Remission without GC
Non-glucocorticoid treatment
100%
18 of 18
Observational data: associations, not effects.
Further findings
Incidence of G-CSF-associated LVV
- 19 of 4708 patients
- 0.4%
Median intervals from last G-CSF administration
- To LVV onset, days (range 2-15)
- 7
- To peak inflammation, days (10-19)
- 14
- To remission, days (14-49)
- 30
- To imaging remission, days (27-346)
- 51
Remission and recurrence, all patients
- All patients achieved remission and experienced no recurrence regardless of treatment
Safety
- NSAID discontinuation owing to liver dysfunction — Non-glucocorticoid treatment
- 1 events
- NSAID discontinuation owing to liver dysfunction — Serious adverse events
- 0
Original publication
Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort. Rheumatology (Oxford). Published 13 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →